FILE:LH/LH-8K-20090305170802.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
On March 5, 2009, Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced that David P. King, Chief Executive Officer, is scheduled to speak at the Barclays Capital Global Healthcare Conference in Miami Beach, FL. LabCorp's presentation is planned for Tuesday, March 10, 2009 at 3:15 p.m. (Eastern Time).
Exhibits
99.1 Press Release dated March 5, 2009
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Exhibit 99.1
 
Telephone: (336) 584-5171
 
LabCorp is Scheduled to Present at the
Barclays Capital Global Healthcare Conference
 
Burlington, NC, March 5, 2009 
Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced that David P. King, Chief Executive Officer, is scheduled to speak at the Barclays Capital Global Healthcare Conference in Miami Beach, FL. LabCorp's presentation is planned for Tuesday, March 10, 2009 at 3:15 p.m. (Eastern Time).
 
A live audio webcast of the presentation will be available via the Company Web site at
www.labcorp.com
and archived for replay.
 
About LabCorp
Laboratory Corporation of America Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.5 billion in 2008, over 28,000 employees worldwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, DIANON
Systems
, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at:
www.labcorp.com
.
 
Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings.
 
 
 
 
 


